You can't always get what you want, but if you try sometimes (with two tests - TST and IGRA - for tuberculosis) you get what you need

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1757-1760

  Winthrop, Kevin L ^a   Weinblatt, Michael E ^b   Daley, Charles L ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; ISONIAZID PLUS RIFAMPICIN; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ALGORITHM; ANKYLOSING SPONDYLITIS; BACTERIAL TRANSMISSION; BCG VACCINATION; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE COURSE; EDITORIAL; HUMAN; INCIDENCE; INFECTION RISK; INFLAMMATORY DISEASE; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM SZULGAI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REFERENCE VALUE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; PROFESSIONAL PRACTICE; TUBERCULIN TEST;

EID: 84867404899     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201979     Document Type: Editorial

References (28)

1. Winthrop KL. The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy. Int J Adv Rheumatol 2010;8:43-52.
2. Smith R, Cattamanchi A, Steingart KR, et al. Interferon-gamma relase assayas for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011.
3. Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection - performance of tuberculin skin test and interferon-gamma release assays under real life conditions. Ann Rheum Dis 2012.
4. Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with exvivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012.
5. Winthrop K, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2012. [Epub ahead of print]
6. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94. Erratum in: Arthritis Rheum.
7. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086-91.
8. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
9. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
10. Winthrop KL, Siegel JN, Jereb J, et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005;52:2968-74. (Pubitemid 41447075)
11. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-52.
12. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
13. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
14. Mazurek G, Jereb JJ, LoBue P, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection, United States 2010. MMWR 2010;59:1-25.
15. Hsia EC, Schluder N, Cush J, et al. Interferon-gamma release assay versus tuberculin skin test across RA, PsA, and AS patients prior to treatment with golimumab, human anti-TNF antibody. Arth Rheum 2012;64:2068-77.
16. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93.
17. Bélard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-9.
18. Vassilopoulos D, Stamoulis N, Hadziyannis E, et al. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6. (Pubitemid 352000770)
19. Vassilopoulos D, Tsikrika S, Hatzara C, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102-8.
20. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81. (Pubitemid 351747116)
21. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114.
22. Matulis G, Jüni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
23. Del Tedesco E, Roblin X, Laharie D, et al. Does anti-TNF therapy influence the performance of Mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience. Inflamm Bowel Dis 2011;17:1824.
24. Gómez-Reino JJ, Carmona L, Angel Descalzo M. Biobadaser group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
25. Chen DY, Shen GH, Chen YM, et al. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Ann Rheum Dis 2012;71:231-7.
26. Winthrop KL, Nyendak M, Calvet H, et al. Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008;3:1357-63.
27. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198-204.
28. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006;28:31-4. (Pubitemid 44914257)